Table 4 Baseline characteristics related to early neurological deterioration after acute cerebral infarction.

From: A prospective cohort study on prognostic implications of serum platelet derived microparticles levels in acute cerebral infarction

 

END

non-END

P value

Age (years)

68.34 ± 5.86

67.53 ± 7.72

0.201

Male

122 (71.35%)

272 (60.44%)

0.617

Body mass index (kg/m2)

25.31 ± 1.58

24.97 ± 1.83

0.031

Systolic blood pressure (mmHg)

138.81 ± 21.10

141.27 ± 20.54

0.284

Diastolic blood pressure (mmHg)

79.87 ± 13.64

80.11 ± 12.06

0.847

Smoker AlcoholAdmission time (hours)

101 (59.06%)

234 (52.00%)

0.115

Blood-collection time (hours)

101 (59.06%)

239 (53.11%)

0.183

Comorbidity

6.40 (5.20–7.60)

6.10 (4.90–7.30)

0.377

 Diabetes mellitus

7.00 (6.20–8.30)

7.30 (6.00–8.50)

0.416

 Hypertension

`

  

 Coronary heart disease

77 (45.03%)

154 (34.22%)

0.013

 Dyslipidemia

90 (52.63%)

267 (59.33%)

0.131

Treatment

63 (36.84%)

139 (30.89%)

0.157

 Thrombolysis

98 (57.31%)

219 (48.67%)

0.054

 Antiplatelet

   

  Statins

60 (35.09%)106 (61.99%)

133 (29.56%)

0.183

 Anticoagulant

32 (18.71%)

297 (66.00%)

0.446

 GLP-1 agonists

10 (5.85%)

93 (20.67%)

0.737

 SGLT2 inhibitorsNIHSS score

13 (8.07%)

32 (7.11%)

0.772

Stroke etiology

34 (21.12%)

24 (5.22%)

0.187

 Small-vessel occlusive

14.00 (12.00–17.00)

81 (17.61%)

0.324

 Large-vessel occlusive

 

12.00 (13.00–16.00)

0.019

 Cardioembolic

42 (24.56%)

 

0.496

 Others

55 (32.16%)

122 (27.11%)

 

 Infarction volume (cm3)

39 (22.81%)

143 (31.78%)

 

TOAST subtype

35 (20.47%)

86 (19.11%)

 

 Large artery atherosclerosis

18.90 (6.40–30.18)

99 (22.00%)

 

 Small artery occlusions

 

13.50 (2.90–25.70)

0.019

 Cardioembolism

52 (30.41%)

 

0.091

Infarct location

93(54.39%)

179 (39.78%)

 

 Anterior circulation infarct

26 (15.20%)

216 (48.00%)

 

 Posterior circulation infarct

 

55 (12.22%)

 

 Lacunar infarct

100 (58.48%)

 

0.060

Laboratory data

44 (25.73%)

216 (48.62%)

 

 Serum triglycerides levels (mg/dL)

27 (15.79%)

138 (30.67%)

 

 Serum total cholesterol levels (mg/dL)

 

96 (21.33%)

 

 Serum HDL-c levels (mg/dL)

100.05 ± 31.92

  

 Serum LDL-c levels (mg/dL)

215.67 ± 42.31

101.51 ± 29.60

0.585

 Serum glucose levels (mg/dL)

50.03 ± 16.53

211.76 ± 52.99

0.372

 Serum PDMPs levels (ng/L)

138.06 ± 35.83

49.24 ± 16.04

0.576

 Platelet count (× 109/L)

122.27 ± 39.82

135.95 ± 45.12

0.573

 APTT (s)

30.31 ± 7.72

115.50 ± 44.06

0.003

 TT (s)

252.84 ± 97.63

25.00 ± 8.15

0.003

 Serum fibrinogen levels (g/L)

28.11 ± 4.43

239.11 ± 90.89

0.092

 

12.36 ± 4.03

27.52 ± 4.21

0.112

 

4.48 ± 1.42

11.98 ± 2.90

0.188

  

4.19 ± 1.60

0.030

  1. Data were shown as counts (percentages), means ± standard deviations or medians (upper-lower quartiles) where appropriate. Intergroup comparisons were done using the Chi-square test, Fisher exact test, Student’s t-test or Mann–Whitney test as appropriate. Abbreviations: END: early neurological deterioration; GLP-1: glucagon-like peptide-1; SLGT 2: sodium-glucose transport protein 2; NIHSS: National Institutes of Health Stroke Scale; TOAST: Trial of Org 10,172 in Acute Stroke Treatment; HDL-c: high-density-lipoprotein cholesterol; LDL-c: low-density-lipoprotein cholesterol; PDMPs: platelet-derived microparticles; APTT: activated partial thromboplastin time; TT: thrombin time.